<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="152671" id="root" date="1996-10-30" xml:lang="en">
<title>USA: Cowen trims Centocor ReoPro expectations.</title>
<headline>Cowen trims Centocor ReoPro expectations.</headline>
<dateline>NEW YORK 1996-10-30</dateline>
<text>
<p>Cowen and Co analyst Joyce Lonergan said on Wednesday she cut her &quot;aggressive&quot; forecasts by 30 percent for 1997 sales of Centocor's blood-clot fighting drug ReoPro.</p>
<p>In a report, Lonergan said that after a meeting with the company, she expected as a result to make &quot;downward revisions&quot; to her earnings per share estimates for Centocor.</p>
<p>She said she expected the company's earnings to be closer to the Wall Street consensus of $0.53 a share for 1997, about 50 percent below her forecast of $1.05, and $1.33 for 1997, below her view of $2.25.  </p>
<p>ReoPro is sold by Centocor's partner Eli Lilly and Co.</p>
<p>&quot;We have been ReoPro bulls and our estimates reflect our admittedly aggressive thinking on the drug, plus positive guidance from (Lilly),&quot; the Cowen report said.</p>
<p>&quot;We believe the key reason for the more gradual than expected, albeit steady, (ReoPro) rollout is that it is taking longer than expected to convince interventional cardiologists, who generally prefer devices to drugs, to use ReoPro,&quot; it added.</p>
<p>The report did not list new ReoPro sales estimates from Cowen, but a September report from the firm had annual sales forecasts of $160 million in 1996, rising to $650 million in 1999.</p>
<p>Lonergan lowered her rating on the stock to neutral from strong buy, saying the revised earnings estimates suggested a fair value at around $30 a share.</p>
<p>The stock was off 1-1/2 to 26-5/8.</p>
<p>--New York Newsdesk, 212-859-1733</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-30"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-30"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-30"/>
  </code>
  <code code="C152">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-30"/>
  </code>
  <code code="C31">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-30"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-30"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-10-30"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-10-30"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="NEW YORK"/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
